Antibody-drug conjugates combined with immunotherapy have redefined the standard of care for advanced bladder cancer, ...

Eli Lilly has signed a new research deal with BigHat Biosciences to co-develop next-generation antibody therapeutics, as the ...

AstraZeneca has been busy in recent years pumping up its oncology pipeline via a shopping list of assets and companies. | ...

Collaboration combines BigHat's AL/ML-powered Milliner™ platform with Lilly's expertise in drug discovery to develop high-quality next-generation antibodies.

In July this year, Genentech submitted a biologic license application to the US Food and Drug Administration (FDA) for the antibody–drug conjugate ... expression to help design our clinical ...

German scientist Paul Ehrlich introduced a groundbreaking concept to the world: chemical compounds could be engineered to ...

Synaffix’s glycan-based antibody–drug conjugate technology is experiencing ... stage and marketed ADC technologies in head-to-head laboratory studies. Experimental in vivo testing in-house ...

New facility is expected to serve as a global hub for accelerating the development of next-generation antibody-drug ...

In this video, Robert DeBernardo, MD, shares insight on antibody-drug conjugates as treatment for patients with cancer, a topic discussed at Society of Gynecologic Oncology Annual Meeting on Women’s ...

plays a pivotal role in the company’s oncology research strategy.The newfacility will serve as a leading research center for advancing antibody-drug conjugates (ADC) research and development, ...

These long-acting, drug-fused IgGs act as excellent peptide ferries, but they are costly because the antibodies must be extracted and modified in a laboratory before they can be effective inside ...